1. Home
  2. PIII vs BRNS Comparison

PIII vs BRNS Comparison

Compare PIII & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo P3 Health Partners Inc.

PIII

P3 Health Partners Inc.

N/A

Current Price

$9.49

Market Cap

33.8M

Sector

Health Care

ML Signal

N/A

Logo Barinthus Biotherapeutics plc

BRNS

Barinthus Biotherapeutics plc

HOLD

Current Price

$0.77

Market Cap

30.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PIII
BRNS
Founded
2015
2016
Country
United States
United States
Employees
N/A
14
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.8M
30.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
PIII
BRNS
Price
$9.49
$0.77
Analyst Decision
Buy
Strong Buy
Analyst Count
4
1
Target Price
$9.00
$4.00
AVG Volume (30 Days)
34.0K
55.1K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,459,080,000.00
N/A
Revenue This Year
$7.67
N/A
Revenue Next Year
$2.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$0.51
52 Week High
$16.89
$1.83

Technical Indicators

Market Signals
Indicator
PIII
BRNS
Relative Strength Index (RSI) 43.00 59.44
Support Level $9.00 $0.65
Resistance Level $11.55 $0.74
Average True Range (ATR) 0.58 0.05
MACD -0.13 0.01
Stochastic Oscillator 34.26 67.06

Price Performance

Historical Comparison
PIII
BRNS

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Share on Social Networks: